REVIEW

Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy

NM Luheshi, NJ Rothwell and D Brough

Faculty of Life Sciences, University of Manchester, Manchester, UK

Dysregulated inflammation contributes to disease pathogenesis in both the periphery and the brain. Cytokines are coordinators of inflammation and were originally defined as secreted mediators, released from expressing cells to activate plasma membrane receptors on responsive cells. However, a group of cytokines is now recognized as having dual functionality. In addition to their extracellular effects, these cytokines act inside the nuclei of cytokine-expressing or cytokine-responsive cells. Interleukin-1 (IL-1) family cytokines are key pro-inflammatory mediators, and blockade of the IL-1 system in inflammatory diseases is an attractive therapeutic goal. All current therapies target IL-1 extracellular actions. Here we review evidence that suggests IL-1 family members have dual functionality. Several IL-1 family members have been detected inside the nuclei of IL-1-expressing or IL-1-responsive cells, and intranuclear IL-1 is reported to regulate gene transcription and mRNA splicing. However, further work is required to determine the impact of IL-1 intranuclear actions on disease pathogenesis. The intranuclear actions of IL-1 family members represent a new and potentially important area of IL-1 biology and may have implications for the future development of anti-IL-1 therapies.

British Journal of Pharmacology (2009) 157, 1318–1329; doi:10.1111/j.1476-5381.2009.00331.x

Keywords: Interleukin-1; nuclear localization; inflammation; disease; IL-1RA; HMGB1

Abbreviations: Bcl-X, B-cell lymphoma-X; CNS, central nervous system; ER, endoplasmic reticulum; HAT, histone acetyl transferase; HMGB1, high mobility group box 1; icIL-1RA, intracellular IL-1RA; IL-1, interleukin-1; IL-1RA, IL-1 receptor antagonist; IL-1RI, type I IL-1 receptor; IL-1RaCP, IL-1 receptor accessory protein; NFkB, nuclear factor kB; NLS, nuclear localization sequence; NPC, nuclear pore complex; sIL-1RA, secreted IL-1RA; SSc, systemic sclerosis; ppIL-1, IL-1 pro-piece

The dual function cytokine hypothesis

Inflammation is required for the efficient clearance of infections and repair of injured tissue, but dysregulated inflammation contributes to the pathogenesis of major peripheral and central nervous system (CNS) diseases. Inflammation is therefore a current focus for drug development. Cytokines, the coordinators of inflammation, were defined originally as soluble mediators, released from an expressing cell to activate transmembrane receptors on responsive cells. However, some cytokines are now known to have an additional set of intracellular (intracrine) actions, either within the expressing cell or following internalization by a responsive cell, and so can be described as having dual functionality (Re, 2003).

High mobility group box 1 (HMGB1) is the prototypical dual function cytokine. First characterized as a nuclear DNA-binding protein that modifies the interactions of transcription factors with DNA (Thomas and Travers, 2001), HMGB1 was later found to be released actively from monocytes in response to pro-inflammatory stimuli (Gardella et al., 2002). In the periphery, released HMGB1 has pleiotropic pro-inflammatory effects, including action as a late mediator of endotoxin lethality in mice (Wang et al., 1999; Lotze and Tracey, 2005). Furthermore, in the brain, blockade of HMGB1 actions by administration of a neutralizing antibody reduces the damage caused by cerebral ischaemia (Liu et al., 2007).

Other cytokines now reported to exhibit dual functionality include interleukin (IL)-16 (Center et al., 2004; Wilson et al., 2005; Zhang et al., 2008) and interferon-γ (Will et al., 1996; Ahmed et al., 2003). Dual function cytokines tend to share certain characteristics, including cytosolic translation, non-classical secretion and nuclear localization in cytokine expressing cells (Cruikshank et al., 2000; Zhang et al., 2001; Ahmed et al., 2003; Lotze and Tracey, 2005).

Interleukin-1 family cytokines are a group of key pro-inflammatory mediators, implicated in the pathogenesis of peripheral and CNS diseases, making the IL-1 system an attractive target for therapeutic intervention. IL-1 family cytokines are assumed to act primarily as secreted mediators,
and all current anti-IL-1 therapeutic strategies target these extracellular IL-1 actions. However, several IL-1 family members localize to cell nuclei and, like HMGB1, may have dual functionality. The intranuclear actions of IL-1 family members remain a poorly understood, potentially important area of IL-1 biology, and will be the focus of this review.

The importance of IL-1 family cytokines in peripheral and CNS disease

The best characterized IL-1 family members are the agonists IL-1α (IL-1F1), IL-1β (IL-1F2), IL-1β (IL-1F4) and the naturally occurring antagonist IL-1RA (IL-1F3, Dinarello, 1996). IL-1β is often described as the prototypical pro-inflammatory cytokine. Released in response to local or systemic injury or disease, IL-1β orchestrates host defence responses. IL-1β has wide-ranging effects on gene expression including up-regulating cytokines, acute phase proteins and tissue remodelling enzymes (Dinarello, 1996). As a key mediator of innate immunity, IL-1β is a potent pyrogen (Murakami et al., 1990) and stimulates neutrophilia and the infiltration of circulating leukocytes into inflamed tissues (Pettilä et al., 1986; Ulich et al., 1987). IL-1β also plays an important role in the adaptive immune response by stimulating the development of activated lymphocytes (Gery et al., 1972).

In the periphery, IL-1β is required for the efficient clearance of bacterial infections (Miller et al., 2007). However, IL-1β is also implicated in the pathogenesis of many acute and chronic peripheral diseases. For example, excessive acute activation of the IL-1β system contributes to the multi-organ failure caused by sepsis (Cohen, 2002). Chronic overproduction of IL-1β is crucial in the familial periodic fever syndromes (Church et al., 2008) and can contribute to the growth, vascularization and metastasis of malignant tumours (Voronov et al., 2003; Elaraj et al., 2006; Krelin et al., 2007). In addition, chronically elevated IL-1β levels are implicated in the pathogenesis of rheumatoid arthritis (Kay and Cabreze, 2004) and chronic obstructive pulmonary disease (Chung, 2001).

Endogenous IL-1β expression in the healthy brain is very low (Vitkovic et al., 2000). The majority of central IL-1β actions occur in the context of neuroinflammation, which leads to an up-regulation of IL-1β expression by microglia, the resident CNS macrophage population (Pearson et al., 1999; Vezzani et al., 1999; De Simoni et al., 2000; Mabuchi et al., 2000). Enhanced IL-1β expression is observed in many acute and chronic neurodegenerative diseases, and IL-1β polymorphisms are linked to altered susceptibility to these diseases (Allan et al., 2005).

The importance of IL-1β in brain injury caused by cerebral ischaemia has been firmly established in animals. Administering exogenous IL-1β exacerbates damage caused by focal cerebral ischaemia in rodents (Yamasaki et al., 1993; Lodick and Rothwell, 1996). Blockade of the IL-1β system with a caspase-1 (an IL-1β processing enzyme) inhibitor, IL-1RA, or a neutralizing antibody for IL-1β, also reduces this damage in rats (Relton and Rothwell, 1992; Yamasaki et al., 1995; Ross et al., 2007). In addition, deletion of the genes for both IL-1α and β, or of caspase-1, substantially reduces ischaemic brain damage in mice, whereas deletion of IL-1RA enhances damage (Schielke et al., 1998; Boutin et al., 2001; Pinteaux et al., 2006).

Interleukin-1β is far more widely studied than IL-1α (there are more than 31 000 papers in the Pubmed database, http://www.ncbi.nlm.nih.gov/sites/entrez, on IL-1β, in comparison with less than 9000 on IL-1α, using the following keyword search: ‘IL-1alpha/beta’ OR ‘IL-1 alpha/beta’ OR ‘Interleukin-1alpha/beta’ OR ‘Interleukin-1-alpha/beta’). This may be due to an assumption that as both cytokines bind and activate the same receptor, they are likely to have redundant effects in vivo (Dinarello, 1997). However, comparison of IL-1α- and IL-1β-deficient mice reveals that these cytokines have non-redundant roles in host defence and disease pathogenesis. Tumorigenesis, turpentine-induced fever and defence against bacterial infection are all dependent on IL-1β but not IL-1α (Horai et al., 1998; Krelin et al., 2007; Miller et al., 2007). In contrast, diet-induced weight gain and atherosclerosis are IL-1α- and not IL-1β-dependent (Kamari et al., 2007). T cell-dependent antibody production is IL-1β-dependent, but the activation of T cells in response to contact allergens is IL-1α-dependent (Nakae et al., 2001a; Nakae et al., 2001b). In addition, IL-1α and β have different, complementary roles in host defence against Campylobacter jejuni infection (Vonk et al., 2006). Different patterns of IL-1α and β expression, processing and release (Lonnemann et al., 1989; Fenton, 1992; Hacham et al., 2000) may all be important in explaining the non-redundant effects of these two cytokines. In addition, as discussed below, the intranuclear actions of IL-1α and β are likely to be different.

Recently, a further seven IL-1 family ligands (IL-1F5-F11) have been identified through sequence homology (Dunn et al., 2001; Schmitz et al., 2005). IL-33 (IL-1F11) acts as an immunomodulator, promoting Th2-type immune responses, and is implicated in the pathogenesis of asthma, rheumatoid arthritis and cardiovascular disease (Kakkar and Lee, 2008). The roles of IL-1F5-10 in host defence and disease pathogenesis remain poorly understood.

IL-1 family members as released mediators

Interleukin-1 family members are commonly assumed to act primarily following release from IL-1 producing cells, via binding transmembrane IL-1 receptors on responsive cells. Mechanisms of IL-1α and β processing and release, and activation of the classical IL-1 signalling pathway on responsive cells, have been reviewed extensively elsewhere (Nichel, 2003; Pridovský et al., 2003; Marialihasan and Monack, 2007; Brikos and O’Neill, 2008) and are summarized here (see Figure 1).

Interleukin-1α and β are unusual secreted proteins, in that they are translated in the cytosol, and have no signal sequence to direct them through the endoplasmic reticulum (ER)-Golgi classical pathway of secretion (Rubartelli et al., 1990; Stevenson et al., 1992). Pro-IL-1β (31 kD) is cleaved to release the active 17 kD mature protein by caspase-1 (Thomberry et al., 1992). Caspase-1 activity is regulated by NOD-like receptors, a family of intracellular pattern recognition receptors that detect pathogen- and damage-associated molecular patterns including gut-associated uric acid crystals, cytosolic

British Journal of Pharmacology (2009) 157 1318–1329

Dual function IL-1 family cytokines

NM Luheshi et al
DNA and bacterial flagellin (Mariathasan and Monack, 2007; Muruve et al., 2008). NOD-like receptor activation leads to oligomerization and recruitment of caspase-1 to a multimeric inflammasome complex, facilitating caspase-1 activation by autoproteolysis (Mariathasan and Monack, 2007).

Pro-IL-1α (31 kD) is released on cell death and, in contrast to pro-IL-1β, can activate IL-1 receptors (Mosley et al., 1987). Pro-IL-1α can also be cleaved by calpains (calcium-dependent proteases, Kobayashi et al., 1990). Heat shock, calcium ionophores and ATP all stimulate the release of mature IL-1α in vitro (Watanabe and Kobayashi, 1994; Perregaard and Gabel, 1998; Mandinova et al., 2003). However, IL-1α release from monocytes is less efficient than IL-1β release in vitro (Lonne mann et al., 1989; Rubartelli et al., 1990), and in vivo many consider IL-1α to be a predominantly intracellular cytokine released only on cell death during severe disease (Dinarello, 1996). This view is supported by the detection of IL-1α-neutralizing autoantibodies in a substantial proportion of healthy humans (5-28%, Saurat et al., 1991; Miossec, 2002). In these individuals, IL-1α-reactive B-cells have evaded immunological tolerance mechanisms that would normally lead to the depletion or inactivation of self antigen-reactive B-cells (Singh and Schwartz, 2006). One explanation for this failure to develop proper immune tolerance to IL-1α is that during immune cell development, IL-1α is retained intracellularly, and so not available extracellularly for identification as a self antigen.

Extracellular IL-1α and β bind and activate the single transmembrane domain type I IL-1 receptor (IL-1RI) on responsive cells (Vigers et al., 1997). Pro-IL-1α, mature IL-1α and mature IL-1β all bind IL-1RI with similar affinity (Kd ∼ 1–10 nM) (Dower et al., 1986; Mosley et al., 1987; McMahan et al., 1991). This triggers IL-1 receptor accessory protein (IL-1RAcP) binding to the IL-1RI/IL-1α/β complex (Wesch et al., 1997). A multi-protein signalling complex is then recruited to the active receptor heterodimer. This signalling complex ultimately activates mitogen-activated protein kinases and nuclear factor κB (NFκB), and so stabilizes mRNA and regulates gene transcription [reviewed in Brikos and O’Neill (2008)]. A more rapid IL-1RI/IL-1RAcP-dependent IL-1β signalling pathway has been observed recently in neurones (Viviani et al., 2003; Davis et al., 2006). IL-1β induces changes in neuronal firing rates through neutral sphingomyelinase activation, and downstream Src kinase-mediated phosphorylation of the NMDA receptor subunit NR2B (Viviani et al., 2003). This rapid signalling pathway is implicated in the febrile response to IL-1β (Sanchez-Alavez et al., 2006).

Interleukin-1RA and IL-1RII are both negative regulators of IL-1α/β signalling. IL-1RA is a competitive antagonist at IL-1RI, which binds to IL-1RI but fails to recruit IL-1RAcP and activate signal transduction (Sims, 2002). IL-1RII acts as a decoy receptor, binding IL-1α and β without activating signalling (Colotta et al., 1993; Rauschmayr et al., 1997). As with IL-1 family ligands, there are a number of newly identified
members of the IL-1 receptor family (Sims, 2002). Some are known to bind new IL-1 family ligands (IL-1F5-F11), while others remain orphan receptors.

**Current anti-IL-1 therapeutic strategies**

The importance of IL-1α and β in the pathogenesis of peripheral and CNS diseases makes the IL-1 system an attractive therapeutic target (Ledford, 2007). The best developed anti-IL-1 therapy is IL-1RA, the naturally occurring antagonist that competes with IL-1α and β for IL-1RI. IL-1RA is approved for the treatment of rheumatoid arthritis in the USA (Kay and Calabrese, 2004) and is currently being developed as a treatment for stroke (Emsley et al., 2005). However, IL-1RA has a short plasma half-life and relatively poor brain penetration, so novel anti-IL-1 therapies are still being investigated [reviewed in Braddock and Quinn (2004)]. These new therapies all target the extracellular actions of IL-1α and β, either by inhibiting IL-1β processing and release or by reducing the bioavailability of IL-1α and β in the extracellular space. However, several IL-1 family members localize to cell nuclei and may regulate intranuclear processes such as transcription and RNA splicing. There follows a review of the evidence for intranuclear roles of IL-1 family members (summarized in Figure 2) and the potential implications for future development of anti-IL-1 therapeutics.

**Intranuclear actions of IL-1α**

The most widely reported intranuclear IL-1 family member is IL-1α. Experiments conducted prior to elucidation of the IL-1 classical signalling pathway indicated that radiolabelled IL-1α was internalized and localized to the nucleus of a number of IL-1-responsive cell lines (Mizel et al., 1987; Grenfell et al., 1989; Curtis et al., 1990; Weitzmann and Savage, 1992). Later, it was shown that IL-1 internalization and nuclear localization were not necessary for classical signalling through IL-1RI (Heguy et al., 1991). However, whether IL-1α endocytosis and nuclear localization have any other role (independent of the classical signalling pathway) has not been investigated further.

Intranuclear IL-1α has also been observed in IL-1α expressing cells (see Table 1). The nuclear entry of cytosolic proteins is regulated by the nuclear pore complex (NPC), a large multi-protein complex spanning the nuclear membrane, which allows free diffusion of proteins smaller than ~50 kD (Paine, 1975; Peters, 1984; Fahrenkrog and Aebi, 2003). Larger nuclear proteins contain one of a range of nuclear localization sequence (NLS) motifs, including the canonical NLS, a short, positively charged sequence of amino acids, allowing their interaction with the nuclear import apparatus. The NLS is bound by cytosolic importins, which facilitate transport across the NPC [reviewed in Stewart (2007)]. This process is driven by gradients of the GDP- and GTP-bound forms of the small GTPase Ran across the nuclear membrane (Izaurralde et al., 1997).

Both pro-IL-1α and β are small enough (31 kD) to diffuse passively across the NPC. However, Wessendorf et al. (1993) made the surprising discovery that the pro-piece of IL-1α (pppIL-1α) contains a canonical NLS, able to target a β-galactosidase fusion protein to the nucleus. Since this discovery of the IL-1α NLS, nuclear localization of pro-IL-1α and pppIL-1α has been reported both in transfected cells and in cells endogenously expressing IL-1α (see Table 1). Indeed
Table 1  The nuclear localization of IL-1 in IL-1-expressing cells

| Cell type/stimulus                  | IL-1 isoform | IL-1 nuclear localization | References                  |
|-------------------------------------|--------------|----------------------------|-----------------------------|
| NIH-3T3 cells                       | pro-IL-1α    | +++                        | Wessendorf et al. (1993)    |
|                                     | ppIL-1α      | ++                         | Maier et al. (1994)         |
| Endothelial cell line               | pro-IL-1α    | +++                        |                             |
|                                     | Mature IL-1α | –                          |                             |
| Perivascular mesangial cells        | pro-IL-1α    | –                          | Stevenson et al. (1997)     |
|                                     | ppIL-1α      | +++                       |                             |
| HEK-293                             | pro-IL-1α    | +++                       | Pollock et al. (2003)       |
| NIH-3T3                             | pro-IL-1α    | +++                       | Werman et al. (2004)        |
| SaOS-2                              | pro-IL-1α    | +++                       | Palmer et al. (2005)        |
| NIH-3T3                             | pro-IL-1α    | +++                       | Sudo et al. (2005)          |
| HEK-293                             | pro-IL-1α    | +++                       | Cheng et al. (2008)         |
| COS-7                               | pro-IL-1α    | +++                       | Luheshi et al. (2009)       |
|                                     | pro-IL-1β    | +                         |                             |
| Endogenous expression               |              |                            |                             |
| Lipid A-treated human mesangial cells | pro-IL-1α    | ++                        | Stevenson et al. (1992)     |
|                                     | pro-IL-1β    | +++                       |                             |
| Untreated brown adipose tissue cells | pro-IL-1α    | +++                       | Burysek and Houstek (1996)  |
|                                     | Mature IL-1α | +++                       |                             |
| Systemic sclerosis fibroblasts      | pro-IL-1α    | +++                       | Kawaguchi et al. (2004)     |
| Untreated vascular smooth muscle cells | pro-IL-1α    | +++                       | Schulte et al. (2007)       |
| Chlamydia trachomatis-infected HeLa cells | pro-IL-1α    | +++                       | Cheng et al. (2008)         |
| LPS-treated microglia               | pro-IL-1α    | +++                       | Luheshi et al. (2009)       |
|                                     | pro-IL-1β    | +                         |                             |

Summary of studies reporting nuclear localization of IL-1α and β isoforms, either when overexpressed (transient or stable transfection) or when expressed endogenously. +++ , ++ , + and – indicate the level of nuclear IL-1 relative to cytosolic IL-1, with +++ indicating a predominantly intranuclear distribution and – an exclusively cytosolic distribution. IL-1 nuclear localization was assessed by cell fractionation, immunocytochemistry and imaging of fluorescent tagged IL-1 fusion proteins.

HEK-293, human embryonic kidney cell line; HeLa, human cervical epithelial cell line; IL-1, interleukin-1; NIH-3T3, murine fibroblast cell line; ppIL-1α, IL-1α pro-piece; SaOS-2, human osteosarcoma cell line.

pro-IL-1α appears to be predominantly intranuclear in many of these cell types.

Intracellular IL-1α is reported to regulate cell proliferation, migration and gene expression (summarized in Table 2). These IL-1α effects have been observed mainly in IL-1α-overexpressing cells and are not inhibited by blockade of extracellular IL-1α actions (using IL-1RA or neutralizing antibodies). The lack of effect of exogenous IL-1α has also been used to exclude involvement of extracellular IL-1α. In some cases, an intranuclear site of action for IL-1α has been more convincingly demonstrated by IL-1α NLS mutagenesis. However, confusion remains as to whether pro-IL-1α or ppIL-1α is the active isoform, the nature of IL-1α intranuclear actions, and the molecular mechanisms through which IL-1α exerts intranuclear effects.

The confusion surrounding the nature of the intranuclear effects of IL-1α is well demonstrated by the various reported roles of intranuclear IL-1α isoforms on cell proliferation. In endothelial cell lines and a human osteosarcoma cell line (SaOS-2), overexpression of pro-IL-1α inhibits cell proliferation (Maier et al., 1994; Palmer et al., 2005). In addition, in HEK-293 (human embryonic kidney cell line) cells and cancer cell lines, overexpression of intranuclear ppIL-1α causes apoptosis (Pollock et al., 2003). However, in other cell types IL-1α appears to promote cell proliferation. Endogenous expression of pro-IL-1α in fibroblasts promotes fibroblast proliferation in systemic sclerosis (SSc) (Kawaguchi et al., 2004; Abraham and Varga, 2005). Furthermore, in perivascular mesangial cells, ppIL-1α overexpression causes malignant transformation, suggesting a role for ppIL-1α as an oncoprotein (Stevenson et al., 1997). In vascular smooth muscle cells, intranuclear pro-IL-1α and ppIL-1α have no effect on proliferation (Beasley and Cooper, 1999). Some of the variables that may explain the contradictory results observed include cell type, IL-1α isoform (pro- vs. ppIL-1α) and expression system (endogenous expression, stable or transient transfection). The role of endogenous intranuclear IL-1α in regulating cell proliferation in vivo remains unknown.

Intracellular pro-IL-1α may also regulate cell migration (McMahon et al., 1997; Merhi-Soussi et al., 2005). However, these two papers report opposite effects of pro-IL-1α on cell migration rates, perhaps reflecting differences in the cell migration assay used (migration following culture wounding vs. migration across a transwell membrane).

The most consistently reported effects of intranuclear IL-1α are on gene expression. In HEK-293 cells, and in murine and human fibroblasts, pro-IL-1α overexpression enhances expression of the pro-inflammatory cytokine IL-6 and/or the chemokine IL-8 (Kawaguchi et al., 2004; Werman et al., 2004; Cheng et al., 2008). In endothelial cells, pro-IL-1α overexpression enhances interferon-γ or tumour necrosis factor α-induced macrophage inhibitory protein 2 expression (Werman et al., 2004). Endothelial cell ppIL-1α overexpression also enhances endogenous IL-1α gene expression, indicating that an intracrine positive feedback loop may operate in these cells (Werman et al., 2004). Endogenous IL-1α has similar intranuclear effects on gene expression. In SSc fibroblasts, endogenous pro-IL-1α enhances IL-6 and collagen...
| Cell type                        | IL-1α isofrom | Intranuclear effect | Evidence that effect is intranuclear | References                  |
|---------------------------------|----------------|---------------------|-------------------------------------|-----------------------------|
|                                 |                | IL-1RA neutralizing Ig | Exog. IL-1α | Expr. mature IL-1α | NLS mutation |
| **Intranuclear IL-1α effects on proliferation/cell death** |                |                      |                      |                |             |
| Endothelial cell line           | pro-IL-1α      | Inhibits proliferation | ✓          | ✕         | ✓          | ✓          | Maier et al. (1994) |
| SaOS-2, human osteosarcoma cell line | pro-IL-1α | Inhibits proliferation | ✓          | ✕         | ✓          | ✓          | Palmer et al. (2005) |
| HEK-293, cancer cells           | ppIL-1α        | Induces apoptosis    | ✕          | ✕         | ✕          | ✕          | Pollock et al. (2003) |
| SSc and normal fibroblasts      | pro-IL-1α      | Enhances proliferation| ✓          | ✓         | ✓          | ✕          | Kawauchi et al. (2004) |
| Perivascular mesangial cells    | ppIL-1α        | Causes malignant    | ✕          | ✕         | ✕          | ✓          | Stevenson et al. (1997) |
| Vascular smooth muscle cells    | pro-IL-1α      | No effect of intranuclear IL-1α on proliferation | N/A | N/A | N/A | N/A | Beasley and Cooper (1999) |
|                                 | mature IL-1α   |                      |                      |                |             |
| **Intranuclear IL-1α effects on gene expression** |                |                      |                      |                |             |
| Endothelial cell line           | pro-IL-1α      | Induces PAI-1 and collagenase expression | ✓          | ✕         | ✓          | ✓          | Maier et al. (1994) |
| NIH-3T3, COS-7, endothelial cell line | pro-IL-1α | Induces IL-6, IL-8 and endogenous IL-1α expression | ✓          | ✕         | ✓          | ✕          | Werman et al. (2004) |
|                                | ppIL-1α        |                      |                      |                |             |
| HeLa, macrophages, HEK-293      | pro-IL-1α      | Induces IL-8 expression | ✓          | ✓         | ✓          | ✕          | Cheng et al. (2008) |
| SSc and normal fibroblasts      | pro-IL-1α      | Induces IL-6 and procollagen expression | ✓          | ✓         | ✓          | ✕          | Kawauchi et al. (2004) |
| **Intranuclear IL-1α effects on cell migration** |                |                      |                      |                |             |
| Endothelial cell line           | pro-IL-1α      | Inhibits migration   | ✓          | ✕         | ✕          | ✕          | McMahon et al. (1997) |
| Endothelial cell line           | pro-IL-1α      | Promotes migration   | ✓          | ✕         | ✓          | ✓          | Merhi-Soussi et al. (2005) |

Evidence that IL-1α effects described involve intranuclear IL-1α. IL-1RA: cell incubation with IL-1RA does not block effect. Exog. IL-1α: application of exogenous IL-1α to cells does not reproduce effect. Neutralizing Ig: incubation of cells with IL-1α-neutralizing antibody does not block effect. Expr. mature IL-1α: expression of mature IL-1α (lacking the NLS) does not reproduce effect. NLS mutation: mutation of IL-1α NLS blocks the effect.

COS-7, African green monkey kidney fibroblast cell line; HEK-293, human embryonic kidney cell line; HeLa, human cervical epithelial cell line; IFNγ, interferon-γ; IL-1, interleukin-1; IL-1RA, IL-1 receptor antagonist; MIP-2, macrophage inhibitory protein-2; N/A, not applicable, as no intranuclear IL-1α effect observed; NIH-3T3, murine fibroblast cell line; NLS, nuclear localization sequence; PAI-1, plasminogen activator inhibitor-1; ppIL-1α, IL-1α pro-piece; SaOS-2, human osteosarcoma cell line; SSc, systemic sclerosis; TNFα, tumour necrosis factor α.
expression (Kawaguchi et al., 2004). In addition, in *Chlamydia trachomatis*-infected HeLa (human cervical epithelial cell line) cells, endogenous pro-IL-1α regulates IL-8 expression (Cheng et al., 2008).

The mechanism by which intranuclear IL-1α regulates gene expression remains unclear. Pro- and ppIL-1α bind histone acetyl transferases (Buryanskova et al., 2004), multifunctional enzymes that can regulate transcription by modifying chromatin structure and acetylation transcription factors such as NFκB (Chan and La Thangue, 2001; Chen et al., 2001). This interaction may explain how pro- and ppIL-1α can transactivate gene expression of a Gal-4 reporter when fused to the Gal-4 DNA-binding domain, and can directly activate NFκB and activator protein-1-dependent transcription (Buryanskova et al., 2004; Werman et al., 2004). ppIL-1α also interacts with necdin (an intranuclear suppressor of growth and collagen production), HAX-1 (HS1-associated protein X-1, a ubiquitously expressed protein with poorly defined functions) and intranuclear IL-1RII (Yin et al., 2001; Hu et al., 2003; Kawaguchi et al., 2006). These interactions are implicated in the intranuclear effects of pro-IL-1α on cell proliferation and gene expression in SSc fibroblasts (Hu et al., 2003; Kawaguchi et al., 2006).

In contrast to these reports that intranuclear IL-1α regulates transcription, Pollock et al. (2003) argue that regulation of RNA splicing underlies the pro-apoptotic effects of ppIL-1α. ppIL-1α localizes to nuclear speckles [storage sites for RNA splicing proteins, reviewed in Lamond and Spector (2003)] and not transcription sites in HEK-293 cells. Pollock et al. (2003) demonstrate that ppIL-1α interacts with various RNA splicing proteins, and that a point mutation blocking this interaction inhibits the pro-apoptotic effects of ppIL-1α. ppIL-1α overexpression caused a shift in the alternative splicing of the apoptosis regulatory gene Bcl-X (B-cell lymphoma-X) from the anti-apoptotic Bcl-XL to the pro-apoptotic Bcl-XS isoform, suggesting a mechanism by which this ppIL-1α interaction may promote apoptosis.

To conclude, the most convincing evidence thus far is for a role in regulating gene expression, possibly through an interaction with histone acetyl transferases. Cell-specific differences in the expression and activation of other transcription and splicing factors would help explain the model-dependent impact of intranuclear pro-IL-1α on the expression of specific genes, and on cell proliferation and migration. However, investigations into the roles of intranuclear IL-1α have remained focused on cell lines overexpressing IL-1α. The question remains as to whether similar or entirely novel IL-1α nuclear effects occur in cells expressing endogenous IL-1α in vivo.

**icIL-1RA isoforms: regulators of IL-1α intranuclear actions?**

Unlike IL-1α and IL-1β, secreted IL-1RA (sIL-1RA, a 17 kD protein variably glycosylated to produce a 22–25 kD protein) has an N-terminal signal sequence that directs its trafficking and secretion through the ER-Golgi. However, three intracellular isoforms of IL-1RA (icIL-1RA 1–3) have been identified that lack this signal sequence and remain intracellular [reviewed in Arend (2002)]. icIL-1RA1 and icIL-1RA2 are generated from alternative transcriptional start sites on the IL-1RA gene. Either one (icIL-1RA1, 18 kD) or two (icIL-1RA2, 25 kD) 5′ exons are transcribed and spliced into an internal splice acceptor site within the first exon of sIL-1RA (Haskill et al., 1991; Muzio et al., 1995). icIL-1RA3 (16 kD) is a truncated variant of sIL-1RA, created either by alternative translational initiation or alternative splicing (Malyak et al., 1998).

The potential actions of these intracellular isoforms remain poorly defined and may be separated into three categories. First, they may be released (Corradi et al., 1995; Levine et al., 1997; Muzio et al., 1999; Wilson et al., 2004; Evans et al., 2006) and act as competitive antagonists for IL-1RI, in a similar manner to sIL-1RA. Recombinant icIL-1RA1 has a similar affinity to sIL-1RA for IL-1RI, whereas icIL-1RA3 has a four- to fivefold lower affinity and so is less likely to act in this way (Malyak et al., 1998). Second, icIL-1RA isoforms expressed in IL-1-responsive cells may antagonize IL-1α- and β-induced signalling through IL-1RI by an intranuclear mechanism (Watson et al., 1995; Garat and Arend, 2003; Banda et al., 2005). Banda et al. (2005) report that icIL-1RA1 interacts with the COP9 signalosome, inhibits COP9 signalosome-associated kinases, and so inhibits cytokine gene expression induced by exogenously applied IL-1α in keratinocyte cell lines. Third, icIL-1RA could antagonize the intranuclear actions of IL-1α. For example, Merhi-Soussi et al. (2005) found that stably co-transfecting icIL-1RA1 with either pro-IL-1α or ppIL-1α blocked the effects of pro- or ppIL-1α on cell migration. Pro-IL-1α can regulate icIL-1RA1 gene expression via an intracellular mechanism, suggesting a negative feedback loop to preventing excessive pro-IL-1α intranuclear action (Higgins et al., 1999). The three intracellular isoforms of IL-1RA may thus have intracellular actions, and in particular may alter the intranuclear actions of IL-1α in IL-1α-expressing cells.

**Intranuclear IL-1β, IL-33 and IL-1F7b**

Pro-IL-1β, in contrast to pro-IL-1α, is commonly viewed as a cytosolic and extracellular cytokine, despite early reports showing the nuclear localization of pro-IL-1β in lipid A-stimulated mesangial cells (Stevenson et al., 1992), and the internalization and nuclear localization of radiolabelled IL-1β by fibroblasts (Qwarstrom et al., 1988). We have recently found that endogenously expressed pro-IL-1β is intranuclear in cultured microglia (Luheshi et al., 2009). In contrast to pro-IL-1α, pro-IL-1β enters cell nuclei by passive diffusion (Luheshi et al., 2009). Whether pro-IL-1β is intranuclear in other cell types remains unknown.

Many pro-IL-1β intranuclear actions reported in the literature are dependent on ppIL-1α, which shares little sequence homology with ppIL-1α (Maier et al., 1994; McMahon et al., 1997; Stevenson et al., 1997; Pollock et al., 2003; Werman et al., 2004; Merhi-Soussi et al., 2005). In addition, ppIL-1β fails to reproduce the apoptosis-promoting effects of intranuclear ppIL-1α (Pollock et al., 2003). These reports support the hypothesis that pro-IL-1β does not have the same intranuclear actions as pro-IL-1α. Whether pro-IL-1β has no
effect on intranuclear processes, or has a separate set of intranuclear actions, remains unknown.

Of the newly identified IL-1 family cytokines, IL-33 (also known as IL-1F11) and IL-1F7b both localize to the nucleus of expressing cells (Carriere et al., 2007; Sharma et al., 2008). IL-1F7b nuclear localization in an overexpressing macrophage cell line correlates with the inhibition of LPS-induced cytokine gene expression (Sharma et al., 2008). IL-33 interacts with chromatin and shows transcriptional repressor activity when overexpressed in cell lines (Carriere et al., 2007). Intranuclear IL-33 is found in resting endothelial cells in vivo, and expression is down-regulated on endothelial activation by pro-inflammatory or angiogenic stimuli (Kuchler et al., 2008; Moussion et al., 2008). This has led some to suggest that transcriptional repression by intranuclear IL-33 helps maintain endothelial cells in a resting state (Kuchler et al., 2008).

Future directions: implications of IL-1 family cytokine dual functionality for future development of anti-IL-1 therapeutics

Thus, in addition to their extracellular effects, several IL-1 family members appear to have intranuclear actions. However, the nature and in vivo consequences of IL-1 family intranuclear actions remain unclear.

The intranuclear mechanisms of action for IL-1α, IL-33, IL-1F7b (and potentially IL-1β) remain poorly described. The most widely studied intranuclear IL-1 family member, IL-1α, appears to regulate gene transcription and RNA splicing. However, further investigation is required into the protein–protein interactions involved in these intranuclear IL-1α actions. In addition, the mechanisms by which IL-1F7b and IL-33 repress transcription remain unknown, and whether IL-1β has any intranuclear effects similarly remains unclear.

Further investigation is also required into the role of IL-1 family member intranuclear actions in vivo. Intranuclear HMGB1 is expressed constitutively in almost all eukaryotic cells, and HMGB1 deficiency is lethal in mice due to the importance of HMGB1 intranuclear actions in development and homeostasis (Calogero et al., 1999).

In contrast to HMGB1, IL-1α and β expression tends to be low in healthy tissues and enhanced by infection or injury (Ulich et al., 1990; Clark et al., 1991). Furthermore, IL-1α- and β-deficient animals develop normally in the absence of an immune challenge (Horai et al., 1998). Thus, intranuclear IL-1α and β actions, like their extracellular actions, are likely to contribute to inflammation during host defence responses or disease pathogenesis. Based on the in vitro studies described above, intranuclear IL-1α may promote abnormal proliferation and excessive collagen production by SSc fibroblasts, contributing to the extensive fibrosis that characterizes the final pathology of this disease (Kawaguchi et al., 2004; Abraham and Varga, 2005; Kawaguchi et al., 2006). However, in vivo evidence to support a role of intranuclear IL-1α or β in any disease is lacking, and identification of conditions under which IL-1α and β localize to cell nuclei in vivo may help identify the potential influence of these intranuclear cytokines on disease progression.

The detection of intranuclear IL-33 in resting endothelial cells indicates that this IL-1 family member may, like HMGB1, play a role in homeostasis (Kuchler et al., 2008; Moussion et al., 2008). However, like IL-1α and β, expression of IL-33 can be induced by pro-inflammatory stimuli (Schmitz et al., 2005; Xu et al., 2008). Whether IL-33 is intranuclear under these conditions remains unknown.

Interleukin-1 family members are key pro-inflammatory cytokines whose extracellular actions are implicated in the pathogenesis of major peripheral and CNS diseases. Current anti-IL-1 therapy is limited to blockade of these extracellular actions. The more recently discovered intranuclear actions of IL-1 family members reviewed here suggest that these cytokines should be considered as dual function mediators. This dual functionality of cytokines represents a novel and potentially biologically important area of cytokine biology. Further investigation will clearly be required to determine the precise nature and importance of IL-1 family intranuclear actions in disease and to assess the therapeutic implications of these intranuclear actions. This could lead to the identification of novel therapeutics to treat inflammatory diseases.

Acknowledgements

We would like to thank Professor Philip Woodman (University of Manchester) for useful discussions. The authors were funded by the British Pharmacological Society (NML), the Medical Research Council (NJR) and the Wellcome Trust (DB, NML).

Conflict of interest

The authors state no conflicts of interest.

References

Abraham DJ, Varga J (2005). Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26: 587–595.
Ahmed CM, Burkhart MA, Mujtaba MG, Subramaniam PS, Johnson HM (2003). The role of IFNgamma nuclear localization sequence in intracellular function. J Cell Sci 116: 3089–3098.
Allan SM, Tyrrell PJ, Rothwell NJ (2005). Interleukin-1 and neuronal injury. Nat Rev Immunol 5: 629–640.
Arend WP (2002). The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13: 323–340.
Banda NK, Guthridge C, Sheppard D, Cairns KS, Muggli M, Bech-Otschir D et al. (2005). Intracellular IL-1 receptor antagonist type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome. J Immunol 174: 3608–3616.
Beasley D, Cooper AL (1999). Constitutive expression of interleukin-1alpha precursor promotes human vascular smooth muscle cell proliferation. Am J Physiol 276: H901–H912.
Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ (2001). Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 21: 5528–5534.
Braddock M, Quinn A (2004). Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 3: 330–339.
activation by interleukin-1 alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 31: 1946–1954.
Kawaguchi Y, Nishimagi E, Tochimoto A, Kawamoto M, Katsumata Y, Soejima M et al. (2006). Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA 103: 14501–14506.
Kay J, Calabrese L (2004). The role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Rheumatol (Oxford) 43 (Suppl. 3): ii12–ii19.
Kobayashi Y, Yamamoto K, Saito T, Kawasaki H, Oppenheim JJ, Matsushima K (1990). Identification of calcium-activated neutral proteinase as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA 87: 5548–5552.
Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M et al. (2007). Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res 67: 1062–1071.
Kuchler AM, Pollheimer J, Balogh J, Sponheijl J, Manley L, Sorensen DR et al. (2008). Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173: 1229–1242.
Lamond AI, Spector DL (2003). Nuclear speckles: a model for nuclear architecture. Nature Rev Mol Cell Biol 4: 605–612.
Ledford H (2007). Fever pitch. Nature 450: 600–601.
Levine SJ, Wu T, Shelhamer JH (1997). Extracellular release of the type 1 intracellular IL-1 receptor antagonist from human airway epithelial cells: differential effects of IL-4, IL-13, IFN-gamma, and corticosteroids. J Immunol 158: 5949–5957.
Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T et al. (2007). Anti-high mobility group box 1 mononclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 21: 3904–3916.
Loddick SA, Rothwell NJ (1996). Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 16: 932–940.
Lonnemann G, Endres S, Van der Meer JW, Cannon JG, Koch KM, Dinsarello CA (1989). Differences in the synthesis and kinetics of release of interleukin 1 alpha, interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur J Immunol 19: 1531–1536.
Lotze MT, Tracey KJ (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5: 331–342.
Luethi NM, Rothwell NJ, Brough D (2009). The dynamics and mechanisms of interleukin-1alpha and beta nuclear import. Traffic 10: 16–25.
Mabuchi T, Kitagawa K, Ihitsuki T, KUwabara K, Yagita Y, Yanagihara T et al. (2000). Contribution of microglia/macrophages to expansion of infarction and resolution of oligodendrocytes after focal cerebral ischemia in rats. Stroke 31: 1735–1743.
McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL et al. (1991). A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 10: 2821–2828.
McMahon GA, Garfinikel S, Prudovsky I, Hu X, Maciag T (1997). Intracellular precursor interleukin (IL)-1alpha, but not mature IL-1alpha, is able to regulate human endothelial cell migration in vitro. J Biol Chem 272: 28202–28205.
Maier JA, Statuto M, Ragnotti G (1994). Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 14: 1845–1851.
Malayk M, Guthridge JM, Hance KR, Dower SK, Freed JH, Arend WP (1998). Characterization of a low molecular weight isoform of IL-1 receptor antagonist. J Immunol 161: 1997–2003.
Mandinova A, Soldi R, Graziani I, Bagala C, Bellum S, Landriscina M et al. (2003). S100A13 mediates the copper-dependent stress-induced release of IL-1alpha from both human U937 and murine NIH 3T3 cells. J Cell Sci 116: 2687–2696.
Mariathasan S, Monack DM (2007). Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat Rev Immunol 7: 31–40.
Merhi-Souss F, Berti M, Wehrle-Haller B, Gabay C (2005). Intracellular interleukin-1 receptor antagonist type 1 antagonizes the stimulatory effect of interleukin-1alpha precursor on cell motility. Cytokine 32: 163–170.
Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H et al. (2007). Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol 179: 6933–6942.
Miossec P (2002). Anti-interleukin 1alpha autoantibodies. Ann Rheum Dis 61: 577–579.
Mizel SB, Killian PL, Lewis JC, Paganeli KA, Chizzonite RA (1987). The interleukin 1 receptor. Dynamics of interleukin 1 binding and internalization in T cells and fibroblasts. J Immunol 138: 2906–2912.
Mosley B, Urda DL, Prickett KS, Larsen A, Conlon PJ et al. (1987). The interleukin-1 receptor binds the human interleukin-1 alpha precursor but not the interleukin-1 beta precursor. J Biol Chem 262: 2941–2944.
Moussion C, Ortega N, Girard JP (2008). The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’? PLoS ONE 3: e3331.
Murakami N, Sakata Y, Watanabe T (1990). Central action sites of interleukin-1beta for inducing fever in rabbits. J Physiol 428: 299–312.
Muruve DA, Pettrilli V, Zais AK, White LR, Clark SA, Ross PJ et al. (2008). The inflammasome recognizes cytokinel and hemoglobin and triggers an innate immune response. Nature 452: 103–107.
Muzio M, Polentarutti N, Sironi M, Poli G, De Gi, Introna M et al. (1995). Cloning and characterization of a new isoform of the interleukin 1 receptor antagonist. J Exp Med 182: 623–628.
Muzio M, Polentarutti N, Facchetti F, Peri G, Dona I, Sironi M et al. (1999). Characterization of type II intracellular IL-1 receptor antagonist (IL-1ra3): a depot IL-1ra. J Immunol 29: 781–788.
Nakae S, Asano M, Horai R, Iwakura Y (2001a). Interleukin-1 alpha, but not interleukin-1 beta, is required for T-cell-dependent antibody production. Immunology 104: 402–409.
Nakae S, Naruse-Nakajima C, Sudo K, Horai R, Asano M, Iwakura Y (2001b). IL-1 alpha, but not IL-1 beta, is required for contact-allergen-specific T cell activation during the sensitization phase in contact hypersensitivity. Int Immunol 13: 1471–1478.
Nickel W (2003). The mystery of nonclassical protein secretion. A current view on cargo proteins and potential export routes. Eur J Biochem 270: 2109–2119.
Paine PL (1975). Nucleocytoplasmic movement of fluorescent tracers microinjected into living salivary gland cells. J Cell Biol 66: 652–657.
Palmer G, Trolliet S, Talabot-Ayer D, Mezin F, Magne D, Gabay C (2005). Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SAos-2 osteosarcoma cells: differential inhibitory effect of interleukin-1 receptor antagonist (IL-1Ra1). Cytokine 31: 153–160.
Pearson VL, Rothwell NJ, Toumoulon S (1999). Excitotoxic brain damage in the rat induces interleukin-1beta protein in microglia and astrocytes: correlation with the progression of cell death. Glia 25: 311–323.
Perreux DG, Gabel CA (1998). Post-translational processing of murine IL-1: evidence that ATP-induced release of IL-1 alpha and IL-1 beta occurs via a similar mechanism. J Immunol 160: 2469–2477.
Peters R (1984). Nucleo-cytoplasmic flux and intracellular mobility in single hepatocytes measured by fluorescence microphotolysis. EMBO J 3: 1831–1836.
Petitpeer ER, Higgs GA, Henderson B (1986). Interleukin 1 induces
leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 83: 8749–8753.

Pintoaux E, Rothwell NJ, Boutin H (2006). Neuroprotective actions of endogenous interleukin-1 receptor antagonist (IL-1ra) are mediated by glia. Glia 53: 551–556.

Pollock AS, Turch J, Lovett DH (2003). The predomain of interleukin-1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J 17: 203–213.

Prudovsky I, Mandinova A, Soldi R, Bagala C, Graziani I, Landicirca M et al. (2003). The non-classical export routes: FGFI and IL-1alpha point the way. J Cell Sci 116: 4871–4881.

Qwarnstrom EE, Page RC, Gillis S, Dower SK (1988). Binding, internalization, and intracellular localization of interleukin-1 beta in human diploid fibroblasts. J Biol Chem 263: 8261–8269.

Rauschmayr T, Groves RW, Kupper TS (1997). Keratinocyte expression of the N-terminal propeptide of interleukin 1 alpha is a transforming nuclear oncoprotein. J Cell Physiol 169: 53–61.

Rubartelli A, Cozzolino F, Talio M, Sitia R (1990). A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence. J Biol Chem 265: 1503–1510.

Sanchez-Alavez M, Tabarean IV, Behrens MM, Bartfai T (2006). Cerebroside mediates the rapid phase of febrile response to IL-1beta. Proc Natl Acad Sci USA 103: 2904–2908.

Saurat JH, Schifferli J, Steiger G, Dayer JM, Didierjean L (1991). Anti-interleukin-1 alpha autoantibodies in humans: characterization, isotype distribution, and receptor-binding inhibition–frequency in Schnitzler’s syndrome (urticaria and macroglome- linia). J Allergy Clin Immunol 88: 244–256.

Schielke GP, Yang GY, Shivers BD, Betz AL (1998). Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 18: 180–185.

Schmitz J, Oowyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. (2005). IL-33, an interleukin-1-like cytokine that signals via ST2 and induces T helper type 2-associated cytokines. Immunity 23: 869–870.

Singh N, Schwartz RH (2006). Primer: mechanisms of immunologic tolerance. Nat Clin Pract Rheumatol 2: 44–52.

Stevenson FT, Torrano F, Locksley RM, Lovett DH (1992). Interleukin-1: the patterns of translation and intracellular distribution support alternative secretory mechanisms. J Cell Physiol 152: 223–231.

Stevenson FT, Turk J, Locksley RM, Lovett DH (1997). The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncprotein. Proc Natl Acad Sci USA 94: 508–513.

Steinman L (2007). Molecular mechanism of the nuclear protein import cycle. Nat Rev Mol Cell Biol 8: 195–208.

Sudo M, Kobayashi Y, Watanabe N (2005). Presence of a cytoplasmatic retention sequence within the human interleukin-1alpha precursor. Zoolog Sci 22: 891–896.

Thomas JO, Travers AA (2001). HMG1 and 2, and related ‘architectural’ DNA-binding proteins. Trends Biochem Sci 26: 167–174.

Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ et al. (1992). A novel heterodimeric cytokine protease is required for interleukin-1 beta processing in monocytes. Nature 356: 768–774.

Ulrich TR, del Castillo J, Keys M, Granger GA, Ni RX (1987). Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes. J Immunol 139: 3406–3415.

Ulrich TR, Guo KZ, Irwin B, Remick DG, Davatelas GN (1990). Endotoxin-induced cytokine gene expression in vivo. II. Regulation of tumor necrosis factor and interleukin-1 alpha/beta expression and suppression. Am J Pathol 137: 1173–1185.

Vezzani A, Conti M, De LA, Ravizza T, Moneta D, Marchesi F et al. (1999). Interleukin-1beta immunoreactivity and microglia are enhanced in the rat hippocampus by focal kainate application: functional evidence for enhancement of electrographic seizures. J Neurosci 19: 5054–5065.

Vithala SP, Anderson LJ, Caffes P, Brandhuber BJ (1997). Crystal structure of the type-1 interleukin-1 receptor complexed with interleukin-1beta. Nature 386: 190–194.

Vitkovic L, Bockaert J, Curic C (2000). The interleukin-1 family cytokines: neuromodulators in normal brain? J Neurochem 74: 457–471.

Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T et al. (2003). Interleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci 23: 8692–8700.

Wilson HL, Francis SE, Dower SK, Crossman DC (2004). Secretion of cytokines. J Cereb Blood Flow Metab 24: 479–490.

Yamashita K, Murthy V, Tatro JB, Beasley D (2007). Endogenous interleukin 1beta and IL-1 beta are crucial for host defense against disseminated candidiasis. J Infect Dis 193: 1419–1426.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.

Yamashita K, Murthy V, Tatro JB, Beasley D, Yamashita K et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100: 2645–2650.
intracellular IL-1 receptor antagonist (type 1) is dependent on P2X7 receptor activation. *J Immunol* 173: 1202–1208.

Wilson KC, Cattel DJ, Wan Z, Rahangdale S, Ren F, Kornfeld H et al. (2005). Regulation of nuclear Prointerleukin-16 and p27(Kip1) in primary human T lymphocytes. *Cell Immunol* 237: 17–27.

Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR et al. (2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells. *Proc Natl Acad Sci USA* 105: 10913–10918.

Yamasaki Y, Matsuura N, Shozuhara H, Onodera H, Itoyama Y, Kogure K (1995). Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. *Stroke* 26: 676–680.

Yin H, Morioka H, Towle CA, Vidal M, Watanabe T, Weissbach L (2001). Evidence that HAX-1 is an interleukin-1 alpha N-terminal binding protein. *Cytokine* 15: 122–137.

Zhang Y, Kornfeld H, Cruikshank WW, Kim S, Reardon CC, Center DM (2001). Nuclear translocation of the N-terminal prodomain of interleukin-16. *J Biol Chem* 276: 1299–1303.

Zhang Y, Tuzova M, Xiao ZX, Cruikshank WW, Center DM (2008). Pro-IL-16 recruits histone deacetylase 3 to the Skp2 core promoter through interaction with transcription factor GABP. *J Immunol* 180: 402–408.